Skip to Main Content

Paper Details

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
Am J Respir Crit Care Med
42
2022
Systemic Sclerosis-Interstitial Lung Disease, Tocilizumab, anti-interleukin-6 receptor antibody, interstitial lung disease, patient, patients, skin sclerosis, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, tocilizumab
Author NameAffiliation
Jonathan G GoldinDavid Geffen School of Medicine, University of California los angeles
Jonathan G GoldinDavid Geffen School of Medicine, University of California los angeles
  • 1 - 2

Datasets

Release 1.2